JP2025121986A5 - - Google Patents
Info
- Publication number
- JP2025121986A5 JP2025121986A5 JP2025077691A JP2025077691A JP2025121986A5 JP 2025121986 A5 JP2025121986 A5 JP 2025121986A5 JP 2025077691 A JP2025077691 A JP 2025077691A JP 2025077691 A JP2025077691 A JP 2025077691A JP 2025121986 A5 JP2025121986 A5 JP 2025121986A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- polypeptide
- collagen
- linker
- binding domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856468P | 2019-06-03 | 2019-06-03 | |
| US62/856,468 | 2019-06-03 | ||
| PCT/US2020/070113 WO2020247974A1 (en) | 2019-06-03 | 2020-06-03 | Methods and compositions for treating cancer with collagen binding drug carriers |
| JP2021571671A JP7680375B2 (ja) | 2019-06-03 | 2020-06-03 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571671A Division JP7680375B2 (ja) | 2019-06-03 | 2020-06-03 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025121986A JP2025121986A (ja) | 2025-08-20 |
| JP2025121986A5 true JP2025121986A5 (cg-RX-API-DMAC7.html) | 2025-12-17 |
Family
ID=73652058
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571671A Active JP7680375B2 (ja) | 2019-06-03 | 2020-06-03 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
| JP2025077691A Pending JP2025121986A (ja) | 2019-06-03 | 2025-05-08 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571671A Active JP7680375B2 (ja) | 2019-06-03 | 2020-06-03 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220298225A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3976111A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7680375B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114173822B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020289485A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021024438A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3144535A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021014932A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020247974A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114206355A (zh) | 2019-06-03 | 2022-03-18 | 芝加哥大学 | 用靶向癌症的佐剂治疗癌症的方法和组合物 |
| WO2024177006A1 (ja) * | 2023-02-20 | 2024-08-29 | 国立大学法人大阪大学 | 細胞にタンパク質付着性を付与する細胞デザイナー分子 |
| US12605394B2 (en) | 2024-07-25 | 2026-04-21 | Visionary Assets, Llc | Compositions containing cannabinoid nanoparticles |
| US12667578B2 (en) | 2024-07-25 | 2026-06-30 | Visionary Assets, Llc | Cryogenic process for making cannabinoid nanoparticles and compositions made thereby |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
| EP0970128A1 (en) | 1997-03-21 | 2000-01-12 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
| ES2706547T3 (es) | 1998-12-23 | 2019-03-29 | Pfizer | Anticuerpos monoclonales humanos para CTLA-4 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| RU2579977C2 (ru) * | 2009-11-13 | 2016-04-10 | Грифольс Терапьютикс Инк. | СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| WO2012112690A2 (en) * | 2011-02-16 | 2012-08-23 | Fabius Biotechnology | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains |
| JP2014022858A (ja) | 2012-07-17 | 2014-02-03 | Murata Mfg Co Ltd | 電力増幅器 |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| WO2015061752A1 (en) | 2013-10-25 | 2015-04-30 | Pharmacyclics, Inc. | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy |
| AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| DK3186284T3 (da) * | 2014-08-28 | 2022-05-09 | Bioatla Inc | Betinget aktive kimæriske antigenreceptorer til modificerede t-celler |
| US10420820B2 (en) * | 2014-09-29 | 2019-09-24 | Counterpoint Biomedia LLC | Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polypeptides |
| CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
| KR20210080460A (ko) * | 2018-10-23 | 2021-06-30 | 드래곤플라이 쎄라퓨틱스, 인크. | 이종이량체성 Fc-융합된 단백질 |
-
2020
- 2020-06-03 CN CN202080055104.6A patent/CN114173822B/zh active Active
- 2020-06-03 JP JP2021571671A patent/JP7680375B2/ja active Active
- 2020-06-03 US US17/596,118 patent/US20220298225A1/en active Pending
- 2020-06-03 CA CA3144535A patent/CA3144535A1/en active Pending
- 2020-06-03 EP EP20818032.3A patent/EP3976111A4/en active Pending
- 2020-06-03 AU AU2020289485A patent/AU2020289485A1/en active Pending
- 2020-06-03 WO PCT/US2020/070113 patent/WO2020247974A1/en not_active Ceased
- 2020-06-03 MX MX2021014932A patent/MX2021014932A/es unknown
- 2020-06-03 BR BR112021024438A patent/BR112021024438A2/pt unknown
-
2025
- 2025-05-08 JP JP2025077691A patent/JP2025121986A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240156894A1 (en) | Stable antibody-drug conjugate, preparation method therefor, and use thereof | |
| Li et al. | Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL | |
| US7033572B2 (en) | Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system | |
| US8920777B2 (en) | Toxins and radionuclides coupled to IGF-1 receptor ligands for treatment of cancer | |
| Curnis et al. | NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors | |
| US11697675B2 (en) | EPHA3 and multi-valent targeting of tumors | |
| JP2021502810A5 (cg-RX-API-DMAC7.html) | ||
| JP2017509594A5 (cg-RX-API-DMAC7.html) | ||
| US20110262466A1 (en) | Compositions containing thrombomodulin domains and uses thereof | |
| CA2230479A1 (en) | Transcytosis vehicles and enhancers for drug delivery | |
| HRP20030192A2 (en) | Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target specific prodrug | |
| JP2022535816A5 (cg-RX-API-DMAC7.html) | ||
| JP2024517871A5 (cg-RX-API-DMAC7.html) | ||
| JP2022520596A5 (cg-RX-API-DMAC7.html) | ||
| AU4104700A (en) | Antibody and chemokine constructs that are directed to CCR5, and their use for treating autoimmune diseases | |
| Corti | Strategies for improving the anti-neoplastic activity of TNF by tumor targeting | |
| She et al. | Snoopligase-catalyzed molecular glue enables efficient generation of hyperoligomerized TRAIL variant with enhanced antitumor effect | |
| Jarvinen et al. | Systemically administered, target-specific therapeutic recombinant proteins and nanoparticles for regenerative medicine | |
| US11952402B2 (en) | Fusion protein containing trail and IgG binding domain and the uses thereof | |
| JP2017095417A (ja) | 抗癌剤 | |
| Liu et al. | Improvement of tumor targeting and antitumor activity by a disulphide bond stabilized diabody expressed in Escherichia coli | |
| US20210179673A1 (en) | Methods and materials for treating cancer | |
| WO2017147820A1 (zh) | 双重标靶药物载体 | |
| US20250382360A1 (en) | Anti-VEGF Single Chain Variable Fusion Protein (RNAT82) | |
| US20250381288A1 (en) | Anti-VEGF Single Chain Variable Fusion Protein (RNAT92) |